Research & Development

Actavis Announces Trial Results

Company reveals outcome of Topline Phase 3 Clinical Trial for Single-Dose DALVANCE' (dalbavancin) in the Treatment of ABSSSI

First-in-Human Phase 1 Trial of MM-141 Demonstrates…

Merrimack Pharmaceuticals, Inc. has announced updated clinical data from a multi-arm Phase 1 study of MM-141, a bispecific antibody targeting…

BCM-95 Curcumin and BosPure Boswellia in Prevention…

In the first study of its kind, researchers have demonstrated novel and previously unknown mechanisms of action

Revolutionary New Concept of Heart Disease Threatens…

Dr. Rath Research Institute: Revolutionary new concept of heart disease threatens end of global statin market